Scholarlink

<p>Over 20% of patients with Alzheimer’s disease (AD) worldwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (<i>n</i> = 425) and Huashan (<i>n</i> = 297), and the North American Alzheimer’s Disease Neuroimaging Initiative cohort (<i>n</i> = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population

  • 期刊论文

  • 发表日期：

    2025年6月23日

查看全文
  • Guoyu Lan,
  • Mengjie Wang,
  • Fernando Gonzalez-Ortiz,
  • Laihong Zhang,
  • Anqi Li,
  • Binyin Li,
  • Mingxing Jiang,
  • Jie Yang,
  • Xuhui Chen,
  • Dai Shi,
  • Xiang Fan,
  • Yue Cai,
  • Pan Sun,
  • Lin Liu,
  • Jieyin Li,
  • Zhengbo He,
  • Lili Fang,
  • Xin Zhou,
  • Linting Chen,
  • Yiying Wang,
  • Mingxu Li,
  • Zhen Liu,
  • Qingyong Wang,
  • Linsen Xu,
  • Liemin Zhou,
  • Guanxun Cheng,
  • Xinlu Wang,
  • Pengcheng Ran,
  • Lu Wang,
  • Kun Sun,
  • Ying Han,
  • Yihui Guan,
  • Kaj Blennow,
  • Fang Xie,
  • Tengfei Guo

摘要

Over 20% of patients with Alzheimer’s disease (AD) worldwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer’s Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.